Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05009862 · ClinicalTrials.gov registry record · Phase 4
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
A Phase 4 study of Peripheral Arterial Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05009862: Active Phase 4 study of Peripheral Arterial Disease, sponsored by Vanderbilt University Medical Center.
NCT05009862 is a Phase 4 study of Peripheral Arterial Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05009862, a Phase 4 study of Peripheral Arterial Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
Primary Outcome
FMD will be measured by forearm high-resolution ultrasonography after treatment with low-dose rivaroxaban plus aspirin and compared to the baseline value following treatment with aspirin plus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aspirin 81Mg Ec Tab
- DRUG Rivaroxaban 2.5 Mg Oral Tablet
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
What the registry record for NCT05009862 still lists
NCT05009862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05009862 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05009862 about?
NCT05009862 is a clinical study titled "The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease". The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
What is the current status of trial NCT05009862?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2022-04-19. Estimated completion is 2026-03-01.
What conditions does trial NCT05009862 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT05009862?
The interventions under investigation include: Placebo (DRUG), Aspirin 81Mg Ec Tab (DRUG), Rivaroxaban 2.5 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05009862?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05009862 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05009862's enrollment target sits among peer trials
75 44th of 79 higher than 36 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Vascular Trial Associated Registry Pilot
RECRUITING · Phase 4
-
The Jetstream G3™ Calcium Study
COMPLETED · Phase 4
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI